MBG453 + NIS793 + Spartalizumab + Decitabine
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis
Conditions
Primary Myelofibrosis, Myelofibrosis, PMF, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Trial Timeline
Nov 30, 2020 → Apr 11, 2024
NCT ID
NCT04283526About MBG453 + NIS793 + Spartalizumab + Decitabine
MBG453 + NIS793 + Spartalizumab + Decitabine is a phase 1 stage product being developed by Novartis for Primary Myelofibrosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04283526. Target conditions include Primary Myelofibrosis, Myelofibrosis, PMF.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04283526 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Primary Myelofibrosis